Inflammatory Biomarker Tracking Predicted to Enhance Response to 3-D Bio-Printed Therapies Expands OneTest for Longevity with Chronic Kidney Disease Risk Assessment GAITHERSBURG, Md., March 24, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”), 20/20 BioLabs (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into an exclusive U.S. technology license ...

Core Insights - 20/20 BioLabs is advancing its patented protein tumor marker (PTM) based, machine learning derived multi-cancer early detection (MCED) methodology, which shows promise for earlier stage cancer detection compared to circulating tumor DNA (ctDNA) based methods [1][4][5] Group 1: MCED Methodology and Findings - Recent studies indicate that protein biomarkers may effectively identify early-stage cancers, addressing the limitations of ctDNA tests, which often fail to detect cancer until it has progressed [3][4] - A large-scale ctDNA-based MCED study in the U.K. has highlighted the biological constraints of ctDNA as a first-line screening tool for early-stage cancers, emphasizing the need for alternative approaches [2][4] - 20/20 BioLabs' OneTest for Cancer has demonstrated detection rates for early-stage cancers as high as 50% for certain tumor types, such as pancreatic and ovarian cancers, in asymptomatic populations [6] Group 2: Validation and Support for Protein Biomarkers - A multicenter validation study published in Nature's Precision Oncology showed consistent cancer signal detection across diverse populations, with measurable sensitivity even in Stage I disease [6] - A blinded validation study at MD Anderson Cancer Center reported that a protein-based multicancer test identified nearly 90% of early-stage lung cancers, indicating the effectiveness of protein tumor markers during early oncogenesis [6] Group 3: Strategic Approach and Future Directions - The company proposes a tiered approach to cancer screening, where protein-based tests like OneTest serve as the initial screening step, followed by ctDNA testing for individuals identified at mild risk [7] - The recent legislation passed by Congress to create a pathway for Medicare coverage of MCEDs starting in 2028 is seen as a significant advancement for cancer screening access [8] - 20/20 BioLabs is committed to building the evidence base for protein-based technologies and working with policymakers to ensure effective screening tools are available [8]

As filed with the U.S. Securities and Exchange Commission on January 21, 2026 Registration No. 333-292125 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 20/20 BIOLABS, INC. (Exact name of registrant as specified in its charter) Delaware 8734 57-2272107 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 15810 Gaither Road, Suite 235 Gaithersburg, MD 20877 ...

As filed with the U.S. Securities and Exchange Commission on December 12, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 20/20 BIOLABS, INC. (Exact name of registrant as specified in its charter) Delaware 8734 57-2272107 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 15810 Gaither ...